Advertisement
Cempra Inc Soars on Market Debut
(Reuters) - Cempra Inc, a clinical-stage pharmaceutical company, managed to garner investors' interests on the first day of trading as the stock opened 4% above its offer price on the Nasdaq.
On Thursday, an underwriter told Reuters the company sold 8.4 million shares at $6 apiece, raising about $50.4 million in proceeds.
Read more.
On Thursday, an underwriter told Reuters the company sold 8.4 million shares at $6 apiece, raising about $50.4 million in proceeds.
Read more.
Advertisement
Advertisement
Advertisement
